Geneos Wealth Management Inc. increased its position in shares of McKesson Co. (NYSE:MCK – Free Report) by 5.6% in the 4th ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a ...

A grant to the University of Illinois Chicago Rockford expands their pharmacy program to focus on rural communities.

Shares of McKesson Co. (NYSE:MCK – Get Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ratings firms that are covering the firm, Marketbeat reports. Two investment ...

McKesson's strategic growth in oncology, biopharma and tech drives momentum in 2025. Will MCK overcome its sustaining challenges with robust finances and innovation?

McKesson's stock appears undervalued, trading at 18 times forward earnings and free cash flow. See why MCK is a Hold.

McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, ...

Evercore ISI analyst Elizabeth Anderson CFA reiterated a Buy rating on McKesson (MCK – Research Report) yesterday and set a price target of ...

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in Q4 and is the fourth lowest scored sector by the SA Quant rating system.

McKesson Corporation (MCK ... of growth from GLP-1 medications and a robust oncology network business. Vertex Pharmaceuticals (VRTX) comes in second with a score of 4.04 and a Buy rating given ...